



**6th International Workshop on
Waldenström's Macroglobulinemia
October 6-10, 2010
Venice, Italy**

Friday, October 8, 2010

Molino Stucky Hilton

Workshop Program

7:00-8:00 AM
Breakfast
Registration

Molino Restaurant
Venetian Foyer (7:00-17:30)

**7:00 AM Consensus Discussions on Treatment Options and Response
Criteria in WM-Part I**

Drs. Owen (UK) and Treon (USA)

Presentation of Current Consensus Treatment Guidelines and Proposed Updates
Dr. Treon (USA)

Refreshments will be available during Consensus Discussions

Session VI Prognostic and Predictive Factors in WM

Session Chair: Dr. Morel (FRANCE)

8:00 AM	Dr. Morel (FRANCE)	Can WM ISS be used to make treatment decisions?
8:10 AM	Dr. Thomas (USA)	ISSMM and ISSWM as prognosticators in WM.
8:20 AM	Dr. Kastiris (GREECE)	Prognostication of the high risk WM patient.
8:30 AM	Dr. Kristinsson (SWEDEN)	Survival in Patients with LPL/WM.
8:40 AM	Dr. Treon (USA)	Fcy polymorphisms and depth of response as predictors of outcome to rituximab based therapy in WM.
8:50 AM	Panel Discussion	All Session VI Speakers.

Session VII Novel Therapeutic Approaches to WM-Preclinical

Session Chair: Dr. Mitsiades (USA)

9:10 AM	Dr. Mitsiades (USA)	Novel Proteasome Inhibitors.
9:20 AM	Dr. Yang (USA)	Preclinical studies of GA101 antibody in WM.
9:30 AM	L. Xu (USA)	Hypomethylation agents in WM.
9:40 AM	Panel Discussion	All Session VII Speakers.

Refreshments will be available during Panel Discussion VIII

Session VIII Treatment of WM- Part I

Session Chair: Dr. Rummel (Germany)

10:00 AM	Dr. Owen (UK)	Phase III Study of Chlorambucil vs. Fludarabine as initial therapy in WM.
10:10 AM	Dr. Tedeschi (ITALY)	Multicenter Study of FCR in untreated & previously treated WM.
10:20 AM	Dr. Rummel (GERMANY)	Primary Therapy of WM with Bendamustine and Rituximab.
10:30 AM	Dr. Hoster (GERMANY)	Frontline Treatment options in WM: German Experience.
10:40 AM	Dr. Treon (USA)	Update on Frontline Treatment Studies in WM.
11:00 AM	Panel Discussion	All Session VIII Speakers

Session IX Treatment of WM-Part II

Session Chair: Dr. Ghobrial (USA)

11:20 AM	Dr. Laszlo (ITALY)	Phase II study of Rituximab and subcutaneous 2CDA in WM.
11:30 AM	Dr. Rossi (FRANCE)	Phase I Study of Atacicept in relapsed/refractory MM and WM.
11:40 AM	L. Ioakimidis (USA)	Maintenance rituximab in WM.
11:50 AM	Dr. Ghobrial (USA)	Update on Salvage Treatment Studies in WM.
12:10 AM	Panel Discussion	All Session XI Speakers

12:30-1:30 PM

Session Break and Lunch.
"Venetian Foyer"

1:00-1:20 PM

Special Lunch Lecturer:
Dr. Stephanie Gregory (USA)
"Novel Treatment Options for B-cell malignancies".

Session X Response Assessment in WM

Session Chair: Dr. Owen (UK)

1:30 PM	Dr. Owen (UK)	Challenges with response assessment in WM.
1:40 PM	Dr. Garcia-Sanz (SPAIN)	Flow cytometric evaluation of WM response.
1:50 PM	Dr. Leleu (FRANCE)	sFLC in response assessment in WM.
2:00 PM	Panel Discussion	All Session VII Speakers.

Session XI Treatment Challenges in WM

Session Chair: Dr. Munshi (USA)

2:20 PM	Challenges in the Management of the WM Patient Dr. Munshi (USA)	
2:30 PM	Debate: Is there a role for nucleoside analogue therapy in WM? YES- Dr. Morra (ITALY)	NO- Dr. Leleu (FRANCE)

- 3:00 PM **Debate: Should Benda-Rituximab be considered the standard as frontline therapy in WM?**
YES- Dr. Rummel (GERMANY) NO- Dr. Leblond (FRANCE)
- 3:30 PM **Debate: Should maintenance rituximab be used for rituximab responders in WM?**
YES- Dr. Advani (USA) NO- Dr. Kimby (SWEDEN)
- 4:00 PM **Debate: Should ASCT be a frontline option for WM?**
YES- Dr. Kyriakou (UK) NO- Dr. Femand (FRANCE)
- 4:30 PM **Debate: Should allogeneic transplant represent a standard of care option in WM?**
YES-Dr. Maloney (USA) NO- Dr. Barlogie (USA)

Refreshments will be available during Debates

- 5:00 PM Dr. Morra (ITALY) Day Summary and Adjournment